Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.

Takamochi K; Suzuki K; Sugimura HFunai KMori HBashar AHKazui T

首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.

【24h】

Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.

机译：吉非替尼治疗后手术切除肺腺癌患者窝藏表皮生长因子受体基因突变。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Gefitinib is the first approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who failed to respond to conventional chemotherapy. Gefitinib has fairly effective anti-tumour activity in patients with tumours harboring EGFR gene mutations. However, there has been no data about the preoperative gefitinib treatment in NSCLC patients. We reported here two cases of surgical resection of residual disease after dramatic response to gefitinib in patients with lung adenocarcinoma harboring EGFR gene mutation. Because both of our patients initially had advanced local tumour burden (bulky N2 disease), complete resection would not have been technically feasible. However, preoperative gefitinib treatment made it possible to achieve complete resection in both patients. We believe that clinical trials are required to evaluate the role of preoperative treatment of EGFR-TKIs in patients with locally advanced NSCLC harboring EGFR gene mutation.

机译：吉非替尼是第一个批准表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗患者的先进非小细胞肺癌(NSCLC)失败对常规化疗。相当有效的抗肿瘤活性肿瘤患者窝藏表皮生长因子受体基因突变。术前吉非替尼治疗非小细胞肺癌病人。切除术后残留病的戏剧性患者对吉非替尼的肺腺癌窝藏表皮生长因子受体基因突变。因为我们的病人最初先进的当地肿瘤负担(笨重N2期疾病),完整切除不会技术上可行。吉非替尼治疗成为可能完整切除病人。这需要临床试验来评估EGFR-TKIs术前治疗的作用局部晚期NSCLC患者窝藏表皮生长因子受体基因突变。

著录项

来源
《Lung cancer: Journal of the International Association for the Study of Lung Cancer》 |2007年第1期|149-155|共7页
作者
Takamochi K; Suzuki K; Sugimura HFunai KMori HBashar AHKazui T;
展开▼
作者单位

First Department of Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 435-3192, Japan.;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类肿瘤学;
关键词
Gene Mutation; Non-Small-Cell Lung Carcinoma; PatientsErbB ReceptorsgefitinibEGFR GeneAdenocarcinoma of lung;

机译：基因突变;非小细胞肺癌癌;PatientsErbB ReceptorsgefitinibEGFRGeneAdenocarcinoma肺癌;

相似文献

外文文献
中文文献

1. Epidermal growth factor receptor mutation analysis in cytological specimens and responsiveness to gefitinib in advanced non-small cell lung cancer patients [J] . Lin Li, Zijin Zhang, Zhixin Bie, 中国癌症研究（英文版） . 2015,第003期
2. Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations [J] . Yan Zhang, Zheng Wang, Xuezhi Hao, 中国癌症研究（英文版） . 2017,第001期
3. Associations Between Epidermal Growth Factor Receptor Gene Mutation and Serum Tumor Markers in Advanced Lung Adenocarcinomas:A Retrospective Study [J] . Ying-qiu Pan, Wei-wu Shi, Dan-ping Xu, 中国医学科学杂志（英文版） . 2014,第003期
4. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases [J] . Shao-bo KE, Hu QIU, Jia-mei CHEN, 当代医学科学(英文) . 2018,第006期
5. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer [O] . Yamada, Tadaaki, Matsumoto, Kunio, Wang, Wei, 2010

机译：Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790m mutant lung cancer

Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.

摘要

著录项

相似文献

相关主题

期刊订阅